



UvA-DARE (Digital Academic Repository)

Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada

Gomes, T.

[Link to publication](#)

Citation for published version (APA):

Gomes, T. (2017). Identifying and evaluating patterns of prescription opioid use and associated risks in Ontario, Canada

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <http://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

Curriculum Vitae and Portfolio

Curriculum Vitae

Tara Gomes was born on February 7, 1982 in Toronto, Canada. She graduated from secondary school at St. John's Kilmarnock in 2000. Following her graduation, she moved to Guelph, Ontario to commence a Bachelor in Sciences degree after receiving the prestigious President's Scholarship from the University of Guelph. During her undergraduate studies, she completed a summer research project in epidemiology that led to her interest in completing graduate work in this area. Tara completed her BSc degree with a major in mathematics and a minor in biology in April 2004 and was awarded with the W.C. Winegard Medal upon graduation. She then pursued a Master's of Health Science in Community Health & Epidemiology at the University of Toronto between September 2004 and December 2005. During this degree, a practicum placement at the Canadian Institute for Health Information introduced her to analysis of large administrative databases, which led to her employment at the Institute for Clinical Evaluative Sciences (ICES) as a biostatistician in 2006. Over the next several years, she worked in both research and the provincial government, gaining expertise in pharmacoepidemiology and health policy. In 2008, she joined the Ontario Drug Policy Research Network as an epidemiologist, and became the Scientific Lead and co-Principal Investigator in 2011. Since this time, Tara has conducted research in a variety of drug policy topic areas, including diabetes, anticoagulation, antipsychotics, and opioids. She is currently a Scientist at ICES and St. Michael's Hospital, and an Assistant Professor at the University of Toronto.

Portfolio

Tara Gomes

January 2011 to March 2017

Supervisors: Prof. Wim van den Brink & Dr. David Juurlink

Publications

PUBLICATIONS IN THESIS

Published

Spooner L, Fernandes K, Martins D, Juurlink DN, Mamdani MM, Paterson JM, Singh S, **Gomes T**. High-dose prescribing and opioid-related hospitalization: a population-based study. PLoS ONE. 2016. 11(12): e0167479.

Gomes T, Paterson JM, Mukati M, Henry D. Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. CMAJ Open. 2015. 3(2): e231-235.

Gomes T, Juurlink DN, Yao Z, Camacho X, Paterson JM, Singh S, Dhalla IA, Sproule B, Mamdani MM. Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. CMAJ Open. Oct 2014. 2(4); E256-261.

Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction. Sept 2014. 109(9); 1482-1488.

Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma: a population-based study. JAMA Intern Med. 2013. 173(3): 196-201.

Gomes T, Paterson JM, Juurlink DN, Dhalla IA, Mamdani MM. Reformulation of OxyContin and Pharmacy Dispensing Patterns near the US-Canada border. Open Medicine. 2012. 6(4) e141-145.

Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Int Med. 2011. 171(7):686-691.

Submitted

Gomes T, Juurlink DN, Mamdani MM, Paterson JM, van den Brink W. Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. Accepted by Drug and Alcohol Dependence.

Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, Opioids and the Risk of Opioid-Related Death: A Population-Based Study. Submitted to PLoS Medicine.

OTHER PUBLICATIONS [FIRST OR SENIOR AUTHOR]

First Author

Gomes T, Martins D, Tadrous M, Paterson JM, Shah BR, Tu JV, Juurlink DN, Chu A, Mamdani MM. Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes: A Population-Based Study. *JAMA Internal Medicine*. 2016. 40(5): 431-435.

Gomes T, Martins D, Tadrous M, Paterson JM, Shah BR, Juurlink DN, Singh SS, Mamdani MM. Self-Monitoring of Blood Glucose: Evaluating the impact of a policy of quantity limits on test strip utilization and costs. *Canadian Journal of Diabetes*. 2016. 40(5): 431-435.

Gomes T, Martins D, Cheng L, Kratzer J, Juurlink DN, Shah BR, Mamdani MM, Paterson JM, Law MR. The impact of policies to reduce blood glucose test strip utilization and costs in Canada. *Canadian Journal of Public Health*. 2015. 106(4): e210-216.

Gomes T, Paterson JM, Mukati M, Henry D. Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. *CMAJ Open*. 2015. 3(2): e231-235.

Gomes T, Juurlink DN, Yao Z, Camacho X, Paterson JM, Singh S, Dhalla IA, Sproule B, Mamdani MM. Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. *CMAJ Open*. Oct 2014. 2(4); E256-261.

Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in high dose opioid prescribing in Canada. *Canadian Family Physician*. Sept 2014; 60(9); 826-832.

Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin treatment for atrial fibrillation. *CMAJ*. 2013. 185(2): e121-127.

Gomes T, Juurlink DN, Shah BR, Hellings CR, Mamdani MM. Progression through diabetes therapies among new elderly users of metformin: a population-based study. *Diabetic Medicine*. 2013. 30(2): e51-55.

- Gomes T**, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among patients treated with warfarin for atrial fibrillation. *Archives of Internal Medicine*. 2012. 172(21): 1687-1689.
- Gomes T**, Juurlink DN, Moore I, Maguire JL, Mamdani MM. The Impact of Federal Warnings on Publically Funded Desmopressin Utilization among children in Ontario. *Journal of Pediatric Urology*. 2012; 8(3):249-53.
- Gomes T**, Juurlink DN, Mamdani MM. Comparative Adherence to Oxybutynin or Tolterodine among Older Patients. *European Journal of Clinical Pharmacology*. 2012; 68(1):97-9.
- Gomes T**, Juurlink D, Mamdani M. Comparative adherence to oxybutynin or tolterodine among older patients [Letter to Editor]. *Eur J Clin Pharmacol*. February 8, 2012. [E-Publication].
- Gomes T**, Juurlink DN, Ho JMW, Mamdani MM. Risk of serious falls associated with oxybutynin and tolterodine: a population-based study. *Journal of Urology*. Oct 2011;186(4):1340-4
- Gomes T**, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioids and dose-related deaths – association or causation? Reply. *Arch Int Med*. 2011. 171(18): 1688-1689.
- Gomes T**, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in Opioid Use and Dosing in the Socioeconomically Disadvantaged. *Open Medicine*. 2011;5(1):E13-E22.

Senior Author

- Kwok H, Khuu W, Fernandes K, Martins D, Tadrous M, Singh S, Juurlink DN, **Gomes T**. The Impact of Drug Insurance Policy on Pregabalin Use: a cross-sectional time series analysis. *Pain Medicine*. 2017. [EPub ahead of print March 6, 2017]
- Martins D, Yao Z, Tadrous M, Shah BR, Juurlink DN, Mamdani MM, **Gomes T** on behalf of the Ontario Drug Policy Research Network. The appropriateness and persistence of testosterone replacement therapy in Ontario. *Pharmacoepidemiology and Drug Safety*. 2017. 26(2): 119-126.
- Knowles S, Lee K, Paterson JM, Shah BR, Mamdani MM, Juurlink DN, **Gomes T**. Self-Monitoring of Blood Glucose: Impact of quantity limits on provincial costs across Canada. *Canadian Journal of Diabetes*. 2016. [EPub ahead of print, December 15, 2016]
- Mast G, Fernandes K, Tadrous M, Martins D, Hermann N, **Gomes T**. Persistence of elderly dementia patients to antipsychotic treatment. *Drugs – Real World Outcomes*. 2016. 3(2): 175-182.

- Foster P, Camacho X, Juurlink DN, Mamdani MM, Martins D, Paterson JM, Vigod S, Yao Z, **Gomes T**. Trends in utilization and costs of antipsychotics among older Ontarians from 2007 to 2013: the effects of the introduction of newer agents and changes in generic status. *CMAJ Open*. 2016. 4(2): E292-E297.
- Tadrous M, Khuu W, Paterson JM, Mamdani MM, Juurlink DN, **Gomes T**. Off-label use of inhaled tobramycin in Ontario, Canada. *Thorax*. 2016. 71(9): 862-864.
- Vaid HM, Camacho X, Granton JT, Mamdani MM, Yao Z, Singh SS, Juurlink DN, **Gomes T**. The Characteristics of Pulmonary Arterial Hypertension Patients in Ontario. *Canadian Respiratory Journal*. 2016. 6279250.
- Tadrous M, Martins D, Lee K, Knowles S, Mamdani MM, Juurlink DN, **Gomes T**. Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: A population-based study. *Expert Reviews in Pharmacoeconomics Outcomes Research*. 2016. 16(6): 803-807.
- Harel Z, Mamdani M, Juurlink DN, Garg AX, Wald R, Yao Z, **Gomes T**. Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. *Can J Cardiol*. 2016. 32(8): 986.
- Gladstone E, Smolina K, Morgan SG, Fernandes KA, Martins D, **Gomes T**. Sensitivity and specificity of administrative mortality data for identifying prescription opioid-related deaths. *CMAJ*. 2016. 188(4): E67-72.
- Ignacy TA, Camacho X, Mamdani MM, Juurlink DN, Paterson JM, **Gomes T**. Professional pharmacy services and patient complexity: an observational study. *Journal of Pharmacy and Pharmaceutical Sciences*. 2015. 18(5): 863-870.
- Amadio A, Lee K, Yao Z, Camacho X, Knowles S, Lay C, Paterson JM, Hunt J, **Gomes T**. Public Drug Coverage and its Impact on Triptan Use across Canada: A Population based study. *Headache*. 2015. 55(Suppl 4): 212-220.
- Khan S, Mascarenhas A, Moore JE, Knowles S, **Gomes T**. Access to Triptans for Acute Episodic Migraine: A Qualitative Study. *Headache*. 2015. 55(Suppl 4): 199-211.
- Knowles S, Oh P, **Gomes T**. Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions. *Headache*. 2015. 55(Suppl 4): 191-198.
- Tung JM, Mamdani MM, Juurlink DN, Paterson JM, Kapral MK, **Gomes T**. Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation. *Stroke*. 2015. 46(4):1120-1122.
- Antoniou T, Yao Z, Camacho XC, Mamdani MM, Juurlink DN, **Gomes T**. Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study. *Pharmacoepidemiol Drug Saf*. 2015. 24(3): 256-261.

- Piszczek J, Mamdani MM, Antoniou T, Juurlink DN, **Gomes T**. The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men. *PLoS One*. July 2014. 9(7): e98003.
- Antoniou T, Zheng H, Singh S, Juurlink DN, Mamdani MM, **Gomes T**. Statins and the risk of herpes zoster: a population-based cohort study. *Clin Infect Dis*. Feb 2014. 58(3): 350-356.
- Foster PD, Mamdani MM, Juurlink DN, Shah BR, Paterson JM, **Gomes T**. Trends in selection and timing of first line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. *Diabetic Medicine*. 2013. 30(10): 1209-1213.

OTHER PUBLICATIONS RELEVANT TO THESIS

- Kaplovitch E, **Gomes T**, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex Differences in Dose Escalation and Overdose Death During Chronic Opioid Therapy: A Population-Based Cohort Study. *PLOS ONE*. 2015. 10(8): e0134550.
- Leece P, Cavacuiti C, Macdonald EM, **Gomes T**, Kahan M, Srivastava A, Steele L, Luo J, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Predictors of Opioid-Related Death During Methadone Therapy. *J Subst Abuse Treat*. 2015. 57: 30-35.
- Eibl J, **Gomes T**, Martins D, Camacho X, Juurlink DN, Mamdani MM, Dhalla IA, Marsh DC. Evaluating Effectiveness of First-time Methadone Maintenance Therapy Across Rural and Urban Regions of Ontario, Canada. *Journal of Addiction Medicine*. 2015. 9(6): 440-446.
- Turner SD, **Gomes T**, Camacho X, Yao Z, Guttman A, Mamdani MM, Juurlink DN, Dhalla IA. Neonatal opioid withdrawal in Ontario. *CMAJ Open*. 2015. 3(1): E55-61.
- Ray JG, Hollands S, **Gomes T**, Urquia M, Macdonald E, Li P, Mamdani MM, Juurlink DN. Risk of overdose and death following codeine prescription among immigrants. *J Epi Comm Health*. Nov. 2014. 68(11); 1057-1063.
- Alam A, **Gomes T**, Bell CM. Long-term Analgesic Use: Sometimes Less Is Not More – Reply. *Arch Int Med*. 2012. 172(15):1189-1190.
- Juurlink DN, **Gomes T**, Guttman A, Hellings C, Sivilotti MLA, Harvey MA, Mamdani MM. Postpartum Maternal Codeine Therapy and the Risk of Adverse Neonatal Outcomes: a retrospective cohort study. *Clinical Toxicology*. 2012. 50(5): 390-395.

Kurdyak P, **Gomes T**, Yao Z, Mamdani MM, Hellings C, Fischer B, Rehm J, Bayoumi AM, Juurlink DN. Use of Other Opioids During Methadone Therapy: A Population-Based Study. *Addiction*. 2012; 107(4):776-80.

Alam A, **Gomes T**, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use following low-risk surgery: A retrospective cohort study. *Archives of Internal Medicine*. Arch Intern Med. 2012 Mar 12;172(5):425-30.

Dhalla IA, **Gomes T**, Mamdani MM, Juurlink DBN. Opioids versus nonsteroidal anti-inflammatory drugs in noncancer pain. *Can Fam Physician*. 2012. 58(1): 30.

Dhalla I, **Gomes T**, Juurlink DN, Mamdani M. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. *Can Fam Phys*. 2011. 57(3):e92-6.

Note: Also co-author on an additional 71 peer-reviewed publications not listed above since 2011

Grants

	Year	Amount
Ontario SPOR Patient-Oriented Research Capacity Building Initiatives Awards Partners in Research: A patient-oriented research capacity building initiative for patients and researchers	2017-2018	\$34,958
Ontario Ministry of Health and Long-Term Care Ontario Drug Policy Research Network*	2016-2017	\$300,000
Canadian Institutes of Health Research Ontario Drug Policy Research Network*	2016-2018	\$1,250,000
Ontario SPOR Support Unit CLEAN-MEDS study	2015-2018	\$1,000,000
Adopting Research To Improve Care (ARTIC) META:PHI Study	2015-2017	\$449,758
Canadian Institutes of Health Research Health mothers, health families	2014-2017	\$133,235
Ontario Ministry of Health and Long-Term Care Ontario Drug Policy Research Network*	2013-2016	\$4,700,000
Canadian Institutes of Health Research 'Take a Minute': Developing an online community of practice and tools to disseminate research evidence on opioid analgesics	2013-2014	\$24,664

Canadian Institutes of Health Research Early evaluation of the new Ontario narcotics monitoring system.	2012-2014	\$98,805
Canadian Institutes of Health Research Pregnancy outcomes among women using antipsychotic drugs.	2012-2013	\$97,708
Ontario Ministry of Health and Long-Term Care Ontario Drug Policy Research Network.	2011-2014	\$2,814,586

**Indicates (co) principal investigator*

Teaching

GUEST LECTURES

Lecture	Year	Workload (hours)
Public Health Agency of Canada Opioid Surveillance Course: Opioid Surveillance and Policy in Canada. Toronto.	2016	10
Introduction to Models and Methods of Research in Clinical, Social & Administrative Pharmacy: Using Health Services Research to Inform Healthcare Practice and Drug Policy, Faculty of Pharmacy, University of Toronto	2016	15
Introduction to Pharmacoepidemiology: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2016	10
Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto (two sessions)	2016	15
Introduction to Basic Descriptive and Inferential Statistics, Faculty of Pharmacy, University of Toronto (2 sessions)	2016	15
Introduction to Pharmacoepidemiology: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2015	10
Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto (2 sessions)	2015	10
Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2014	10
Introduction to Basic Descriptive and Inferential Statistics, Faculty of Pharmacy, University of Toronto	2013	10
Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2013	10
Graduate Seminar Series: Opioids in Ontario: Past, Present and Future. Graduate Seminar. Leslie Dan Faculty of Pharmacy, University of Toronto	2013	15

Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2012	10
Graduate Seminar Series: Controlling for unmeasured confounding in observational research: High dimensional propensity score matching	2012	15
Introduction to Basic Descriptive and Inferential Statistics, Faculty of Pharmacy, University of Toronto	2012	10
Critical Appraisal: Nested Case-Control Study Designs, Faculty of Pharmacy, University of Toronto	2011	10
Introduction to Basic Descriptive and Inferential Statistics, Faculty of Pharmacy, University of Toronto	2011	15

TUTORIAL INSTRUCTOR

Course	Year	Workload (Hours)
HAD5306: Introduction of Health Care Research Methodology. Institute for Health Policy, Management and Evaluation, University of Toronto	2015	80
HAD5306: Introduction of Health Care Research Methodology. Institute for Health Policy, Management and Evaluation, University of Toronto	2014	80
HAD5306: Introduction of Health Care Research Methodology. Institute for Health Policy, Management and Evaluation, University of Toronto	2013	80
HAD5306: Introduction of Health Care Research Methodology. Institute for Health Policy, Management and Evaluation, University of Toronto	2012	80

SUPERVISING

Student, Degree Type	Start of Supervision	Position	Workload (Hours)
Andrea Mastorakos, <i>BSc</i>	2016	Undergraduate Research Practicum	60
Rajwant Minhas, <i>PharmD</i>	2016	PharmD Research Rotation	50
Megan Harbin, <i>PharmD</i>	2016	PharmD Research Rotation	50
Lulu Gao, <i>PharmD</i>	2016	PharmD Research Rotation	50
Qi Guan, <i>MSc</i>	2015	Masters Co-Supervisor	200
Mike Benusic, <i>MD</i>	2015	Residency Research Elective (Co-Supervisor)	40
Herman Kwok, <i>PharmD</i>	2015	PharmD Research Rotation	60
Gavin Mast, <i>BSc</i>	2015	Summer Studentship Research Project	60

Luke Spooner, <i>BSc</i>	2015	Summer Studentship Research Project	60
Bindu Nair, <i>MD</i>	2015	Graduate Research Practicum	60
Jennifer Tung, <i>PharmD</i>	2014	PharmD Research Rotation	50
Anthony Alamadio, <i>PharmD</i>	2014	PharmD Research Rotation	50
Teegan Ignacy, <i>PharmD</i>	2013	Research Project	40
Paul Foster, <i>Medical Student</i>	2013	Research Project	40
Haris Vaid, <i>BSc</i>	2013	Research Project	40
Jolanta Piszczek, <i>PharmD</i>	2012	PharmD Research Rotation	50
Stephen Cornish, <i>Medical Student</i>	2012	Research Project	40
Aleesa Carter, <i>PharmD</i>	2012	PharmD Research Rotation	50

PhD Training

COURSES AND SEMINARS

	Year	Workload (Hours)
University of Toronto Science Leadership Program	2015	30
Scientist Knowledge Translation Training program	2016	8
American Academy of Clinical Toxicology Webinar: Postmortem Toxicology - What Every Toxicologist Should Know	2016	1

Presentations

PUBLIC LECTURES

1. Measuring impacts of implementing quantity limits for blood glucose test strips in Canada. Sunnybrook Endocrinology Rounds, Toronto, Ontario. March 9, 2017.
2. Opioid Use and Overdose in Ontario: Measuring Policy Impact and Public Health Implications Public Health Ontario Grand Rounds, Toronto, Ontario. November 8, 2016.
3. Leveraging Regularly Collected Data for Opioid Surveillance and Policy Evaluation. SAS Health User Group, Toronto, Ontario. April 8, 2016.
4. Opioid Use and Misuse in Ontario. A public online webinar organized by the Ontario Drug Policy Research Network. March 9, 2015. [114 online attendees from across North America]

5. Drug Policy Research in Canada: The Ontario Drug Policy Research Network. Centre of Research Excellence in Medicines and Ageing Seminar Series. University of Sydney, Australia. June 20, 2014.
6. Canadian Network for Observational Drug Effect Studies: Focus on dispensing of oral opiate medications at pharmacies close to USA border crossings. Institute for Clinical Evaluative Sciences Rounds. Toronto, Ontario. May 6, 2014.
7. Bridging Research and Drug Policy: The Ontario Drug Policy Research Network. St. Michael's Hospital Clinical and Population Research Rounds. November 28, 2013.
8. Opioids in Ontario: Past, Present and Future. ICES Rounds. Toronto, Ontario. May 28, 2013
9. High Dose Opioid Prescribing and Associated Risks in Ontario, Canada. FDA public meeting on the Impact of Approved Drug Labeling on Chronic Opioid Therapy, Bethesda, Maryland, USA. February 7, 2013.
10. Opioids and Dose: Trends, Risks, and Provincial Variation. ICES Mental Health and Addictions Rounds, Toronto, Ontario. November 28, 2012.

INVITED PRESENTATIONS TO GOVERNMENT

1. Canada's Opioid Epidemic. Presented to Member of Parliament Sonia Sidhu, Toronto, Ontario. October 6, 2016.
2. Opioid use and high strength formulations in Ontario. Presented to the Ontario Palliative Care Network-ODB engagement meeting. Sept 20, 2016.
3. Opioid use and high strength formulations in Ontario. Ontario Drug Benefit Program Changes to High-Strength Opioid Funding Stakeholder Meeting, Toronto, Ontario. August 16, 2016.
4. Introduction to Drug Policy Research. Presented to the ODPRN Citizens' Panel. August 9, 2016. Toronto, ON. Co-presenter: Mina Tadrous
5. The Ontario Drug Policy Research Network & the OPDP/CED: Identifying Opportunities for Research. Committee to Evaluate Drugs, Toronto, Ontario. July 13, 2016.
6. Methadone and Buprenorphine in Ontario: Patterns of Use and Quality of Care. Methadone Treatment and Services Advisory Committee, Toronto, Ontario. March 10, 2016.
7. Treatment of Overactive Bladder and Treatment of Adult ADHD. Committee to Evaluate Drugs, Toronto, Ontario. April 13, 2016.
8. Cognitive Enhancers for Alzheimer's Disease and Antipsychotics for Dementia. Committee to Evaluate Drugs, Toronto, Ontario. February 10, 2016.

9. Treatments for Chronic Hepatitis B: Drug Class Review. Committee to Evaluate Drugs, Toronto, Ontario. January 13, 2016.
10. ODPRN Evaluation of SMBG Quantity Limits. Ontario SMBG Working Group. June 15, 2015.
11. SMBG Utilization and Costs in Ontario. Past work and future directions. Ontario SMBG Working Group. April 17, 2015.
12. Drug Class Review: Triptans for acute migraine management. Committee to Evaluate Drugs, Toronto, Ontario. June 11, 2014.
13. Ontario Drug Benefit and Narcotics Monitoring System: Learning Session. Meeting with the Health Analytics Branch of the Ontario Ministry of Health and Long-Term Care. June 2, 2014.
14. Use of LAMA products in Ontario. Committee to Evaluate Drugs, Toronto, Ontario. May 7, 2014.
15. Patterns of use of prescription opiates in Canada before and after introduction of tamper- deterrent oxycodone. Meeting with the Federal Ministry of Health on Opioid Prescribing in Canada. February 10, 2014
16. Patient complexity and use of pharmacy services. Ontario Pharmacy Council. January 9, 2014.
17. The Ontario Drug Policy Research Network: Public Engagement and the Ontario Citizen's Council. Ontario Citizen's Council. November 1, 2013.
18. The Ontario Drug Policy Research Network. Ontario Pharmacy Council. September 20, 2013.
19. Second-line cholesterol lowering medications and statin use. Committee to Evaluate Drugs, Toronto, Ontario. June 12, 2013.
20. ODPRN: Current Status and Future Directions. Committee to Evaluate Drugs, Toronto, Ontario. May 8, 2013
21. Opioid Prescribing in Ontario. Committee to Evaluate Drugs Annual Retreat, Toronto, Ontario. February 5, 2013.
22. ODPRN Update to the CED. December 2012. Committee to Evaluate Drugs, Toronto, Ontario. December 14, 2012.
23. Long-Acting Oxycodone: Prescribing Patterns in Ontario. Committee to Evaluate Drugs, Toronto, Ontario. December 14, 2011.
24. Trends and Consequences of Opiate Prescribing in Ontario. Ontario Public Drug Program Branch Meeting. Toronto, ON. December 1, 2011
25. Managing the Formulary: Self-Monitoring of Blood Glucose. Ontario Citizen's Council Meeting. Toronto, ON. April 15, 2011.

OTHER INVITED PRESENTATIONS

1. Keynote Address: Opioid Surveillance and Monitoring the Impacts of Drug Policy in Canada. Centre for Addiction and Mental Health PMAP Conference. Toronto, Ontario. March 5, 2017.
2. Measuring Drug Harms using Linked Administrative Data in Canada – Challenges and Opportunities. Presentation at Best Brains Exchange on topic of Supporting Evidence-Informed Drug Policy: Developing a Canadian Drugs Observatory. Ottawa, Ontario. October 3, 2016
3. Contributions of Drug Safety and Effectiveness Data to Healthcare Practice and Policy. DSECT Symposium. April 27, 2016.
4. Opioid Surveillance and Policy: A Canadian Perspective. Prescription Drug Overdose Summit. University of Michigan. December 1, 2015. [over 400 attendees from across North America]
5. Keynote Address: Increase in Opioid Related Deaths: What the Data Can Tell Us. CPSO Methadone Prescribers' Conference. November 7, 2014.
6. Keynote Address: Practicalities of establishing and maintaining a successful drug safety and utilization research network. Drug Safety Colloquium, University of Otago, New Zealand. June 25, 2014.
7. Keynote Address: Drug safety and utilization research based on routinely collected data: some examples from Ontario. Drug Safety Colloquium, University of Otago, New Zealand. June 25, 2014.
8. Plenary Speaker: National Perspective – how can we use observational research today? Real World Evidence: System Readiness. Institute of Health Economics. April 6, 2014.
9. Opioid use and misuse in Ontario: Issues and latest trends. Ontario Harm Reduction Conference. January 28, 2014.
10. The Ontario Drug Policy Research Network. Ontario Medical Association. November 12, 2013.
11. Pharmaceutical misuse and its challenges: opioid use in Ontario. Ontario Harm Reduction Conference. January 31, 2012.
12. Trends and Consequences of Opiate Prescribing in Ontario. Centre for Addiction and Mental Health. Toronto, ON. September 27, 2011
13. Effectiveness of the CPSO Opioid Prescribing Course. CPSO Education Committee. January 17, 2011.

CONFERENCE PRESENTATIONS

1. Opioid Utilization and Opioid-Related Deaths in Ontario. 2015 HSRF Showcase. Toronto, Ontario. February 23, 2015.
2. Using Coroners' data to enrich health administrative data to assess the burden of opioid-related mortality in Ontario. 2014 International Health Data Linkage Conference. Vancouver, B.C. April 29, 2014.
3. Evidence-based Tools for Policy-Makers: The Impact of Warnings, Academic Publications and Formulary Restrictions on Drug Prescribing in Ontario. 2011 CADTH Symposium. Vancouver, B.C. April 4, 2011.
4. Opioid dose and drug-related mortality in patients with nonmalignant pain. ISPE Rapid Drug Safety Monitoring Symposium. April 1, 2011.

Committee and Expert Panel Membership

	Year
Health Quality Ontario. Opioid Prescribing for Pain Quality Standard Advisory Committee. Toronto, Ontario.	2017-present
CIHR Best Brains Exchange. Supporting Evidence-Informed Drug Policy: Developing a Canadian National Drugs Observatory. Ottawa, Ontario	2016
Canadian Institute for Health Information Forum on Prescription Drug Abuse Priority Information Needs. Toronto, Ontario	2016
Leslie Dan Faculty of Pharmacy. Committee on Academic Standing. University of Toronto, Toronto, Ontario	2016-present
Ontario Ministry of Health and Long-Term Care. Methadone Treatment and Services Advisory Committee. Toronto, Ontario	2016
Health Canada. Committee for Improving Canadian Family Physician Knowledge and Performance in Safe Prescribing of Opioids for Chronic Non-Cancer Pain. Toronto, Ontario	2015-present
United States Department of Transportation, Federal Motor Carrier Safety Administration. Medical Expert Panel. Schedule II Opioids and Stimulants & CMV Crash Risk and Driver Performance.	2014
United States Food and Drug Administration. Expert Panel. Postmarketing Requirements for the Class-wide extended-release/long-acting opioid analgesics. Bethesda, Maryland	2014
St. Michael's Hospital. Surviving Opioid Overdose with Naloxone. Toronto, Ontario	2014
Health Quality Ontario. Ontario Health Technology Assessment Committee Patient Engagement Subcommittee. Toronto, Ontario	2013-2014

Awards

1. **2016 Canada Health Infoway Data Impact Challenge II. Best Answer Award**, Chronic Opioid Use category.
2. **2015 Recognition as one of Pharmacoepidemiology and Drug Safety's Best Reviewers of the year.**
3. **2015 Institute for Public Administration of Canada's 2014 Bronze Public Sector Leadership Award** for the Ontario Drug Policy Research Network
4. **2013 St. Michael's Hospital Arthur Award** for Project with Highest Research Impact.
5. **2009 Bruce Squires Award (CMAJ)** for article most likely to influence clinical practice